Adoptive cellular immunotherapies are revolutionary in the treatment of hematological cancer, but obstacles such as tumor heterogeneity and the microenvironment remain challenging to play an effective role in solid tumors.9 Chimeric antigen receptor (CAR) therapies show promising results in brain tumors, for example, 50% of patients with recurrent high-grade glioma achieve stable disease or better following treatment with IL-13Rα2 targeted CAR-T-cells.10 However, the hurdles related to CAR-T-cell therapies are similar to other solid tumors. This evidence concerns the gene IL13RA2 and brain neoplasm.